 |
|
 |
|
| MarketVIEW: Norovirus vaccines |
|
|
|
Published: July 2025
Noroviruses (NoVs) called Norwalk-like viruses are a group of single-stranded positive sense RNA viruses and members of the family Caliciviridae.
Noroviruses are transmitted from human-to-human (fecal-oral) and via food sources. They are one of the most highly infectious viruses known.
In the community, NVs most commonly cause a self-limiting mild disease
of short duration with gastrointestinal symptoms, usually resolving after 1 to 3 days. However, in infants, elderly and immunocompromised persons dehydration occurs requiring medical attention and/or hospital admission for the administration of IV fluids.
Globally, norovirus is associated with approximately one-fifth of all diarrhea cases, with similar prevalence in both children and adults. It is the 2nd most common cause of death in children <5 yrs and the most common cause of diarrheal death in children >5 yrs with similar patterns across WHO regions (100-200k deaths, all ages annually and around 700 million illnesses). NoV outbreaks are also a well-known issue in confined environments such as long-term care facilities, hospitals, military installations and commercial cruise ship liners. In these cases, the virus can cause severe disruption and economic loss. New pandemic norovirus strains such as the emergence of GII.17 over GII.4 heighten the need for continued surveillance and interventions beyond supportive care.
Because of the success of the rotavirus vaccine reducing diarrheal disease burden, it is hoped a new norovirus vaccine can have a similar impact, now that the virus has taken a more prominent role. The most advanced Western program is now operated by ModernaTX (mRNA-1403/05) now at Phase 3 testing. Both HilleVax (HIL-214/216, previously Takeda/Ligocyte) and Vaxart (oral adenovirus) are in clinical stages of testing but have encountered various setbacks. Chinese developers (e.g. NVSI) are also pressing ahead with late stage clinical studies.
This MarketVIEW product is a comprehensive Executive presentation + MS Excel-based model(s), which forecasts the potential commercial value of Norovirus vaccines across 113 major Western and emerging markets and GAVI to 2039*.
The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates for all major market segments. There is a thorough review of global epidemiology, economic burden,
competitive vaccine landscape. Brand new model scenarios explore segment prioritization (post-COVID-19), vaccine duration of immunity and various new adjustments.
This product is ideally suited to those organisations wanting an extended, up-to-date global forecast for this vaccine opportunity.
THIS PRODUCT IS A EXECUTIVE PRESENTATION (>300 slides, .pdf) + scenario MODEL(s)
Photo Credit: Peter Hansen on Unsplash
*some countries are rolled up
To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com
| CAT No: |
CONTENTS: |
PURCHASE: |
| VAMV015 |
Contact us |
Contact us |
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations).
Please review the TERMS and CONDITIONS of purchase.
|
|
|
|
|
|
